

ASX / MEDIA ANNOUNCEMENT

15 November 2021

**Results of 2021 Annual General Meeting**

**Respiri Limited (ASX:RSH) ("Respiri" or the "Company")**, an eHealth SaaS Company supporting respiratory health management, is pleased to announce the results of its Annual General Meeting held today.

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the details of the resolutions and the proxies received in respect of each resolution are set out in the attached summary.

Mr Alastair Beard  
Company Secretary  
Respiri Limited

- ENDS -

For further information, investors and media please contact:

**Mr Marjan Mikel**  
CEO & Managing Director  
Respiri Limited  
P: +61 408 462 873  
E: [marjan@respiri.co](mailto:marjan@respiri.co)

**Mr Nicholas Smedley**  
Executive Chairman  
Respiri Limited  
P: +61 447 074 160  
E: [nicholas@respiri.co](mailto:nicholas@respiri.co)

*This ASX announcement dated 15 November 2021 has been authorised for release by the Board of Directors of Respiri Limited.*

## About Respi Limited

Respi is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo®, Respi's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo® is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians and other health care professionals.

Respi's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respi Limited's operations are based in Melbourne, Australia.

For additional information about Respi and its products, please visit [www.respi.co](http://www.respi.co)

## About wheezo®

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo® device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

For further information about wheezo, follow the online link <https://wheezo.com>

® wheezo is a registered trademark of Respi Limited.

**RESPIRI LIMITED**  
**2021 Annual General Meeting**  
**Monday, 15 November 2021**  
**Results of Meeting**

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Remuneration Report	Ordinary	112,606,405 96.38%	2,978,941 2.55%	1,245,983 1.07%	208,667	113,852,388 97.45%	2,978,941 2.55%	782,444	Carried
2 Re-election of Marjan Mikel as a Director	Ordinary	114,159,846 96.95%	2,347,157 1.99%	1,245,983 1.06%	32,464	115,405,829 98.01%	2,347,157 1.99%	32,464	Carried
3 Approval of 10% Placement Capacity	Special	113,242,321 96.31%	3,088,443 2.63%	1,245,983 1.06%	208,703	114,488,304 97.37%	3,088,443 2.62%	208,703	Carried

\* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.